News

A $8 billion-dollar class action investors’ lawsuit against Meta CEO Mark Zuckerberg and company leaders begins, with claims ...
Diageo CEO Debra Crew has stepped down and finance chief Nik Jhangiani has taken over in the interim, the company said on Wednesday, as the world's biggest spirits maker strives to boost performance ...
An $8 billion trial by Meta Platforms shareholders against Mark Zuckerberg and other current and former company leaders kicks ...
The communications, community engagement and compliance tech company has launched its first AI chatbot, and the company’s CEO ...
Executive protection must evolve from reactive responses to proactive strategies, encompassing digital, insider, and ...
The results position Hengrui to seek approval of the Zepbound-like drug in China and Kailera, a well-funded biotech startup, ...
Now that the data is going to a 23andMe-adjacent nonprofit, which is also making similar promises, I guess nothing much has ...
States with privacy objections to the sale have until July 7 to reach a stay to appeal the case. TTAM, a nonprofit started by ...
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory ...
A bankruptcy court has approved the sale of 23andMe to TTAM Research Institute for $305 million following a bankruptcy filing in March.
Study Overview: Bayer AG and Regeneron Pharmaceuticals are conducting a Phase 4 study titled An Open-label, Non-randomized, Multi-center, Phase 4 Pharmacokinetic Study to Evaluate the Systemic ...